Related references
Note: Only part of the references are listed.Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
S. Gourgou-Bourgade et al.
ANNALS OF ONCOLOGY (2015)
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
C. A. Bellera et al.
ANNALS OF ONCOLOGY (2015)
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
Franck Bonnetain et al.
EUROPEAN JOURNAL OF CANCER (2014)
Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future
Sumanta K. Pal et al.
ONCOLOGIST (2014)
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials
Carine A. Bellera et al.
EUROPEAN JOURNAL OF CANCER (2013)
Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival
Helgi Birgisson et al.
BMC CANCER (2011)
Issues in Using Progression-Free Survival When Evaluating Oncology Products
Thomas R. Fleming et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Survival end point reporting in randomized cancer clinical trials: A review of major journals
Simone Mathoulin-Pelissier et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer
R. A. Nout et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Share Paper
